Canada Post Corp Registered Pension Plan Buys 54,231 Shares of Gilead Sciences, Inc. $GILD

Canada Post Corp Registered Pension Plan increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 110.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 103,344 shares of the biopharmaceutical company’s stock after buying an additional 54,231 shares during the period. Canada Post Corp Registered Pension Plan’s holdings in Gilead Sciences were worth $11,639,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in GILD. Norges Bank acquired a new position in Gilead Sciences in the 2nd quarter valued at $2,150,268,000. Ameriprise Financial Inc. increased its position in Gilead Sciences by 397.6% during the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after acquiring an additional 5,392,191 shares during the period. Invesco Ltd. raised its stake in Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after purchasing an additional 3,394,330 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in Gilead Sciences by 164.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock valued at $387,286,000 after purchasing an additional 2,169,266 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Gilead Sciences by 1.6% during the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after purchasing an additional 1,893,401 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Citigroup boosted their price target on Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Daiwa Securities Group boosted their price target on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Argus increased their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research report on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $136.73.

Insider Transactions at Gilead Sciences

In other news, EVP Deborah H. Telman sold 53,646 shares of Gilead Sciences stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the sale, the executive vice president directly owned 43,676 shares of the company’s stock, valued at approximately $5,365,596.60. This trade represents a 55.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the transaction, the chief executive officer owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. This trade represents a 16.95% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 373,037 shares of company stock valued at $50,731,512. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $152.50 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $153.13. The stock has a market cap of $189.20 billion, a PE ratio of 23.64, a PEG ratio of 0.79 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The firm’s fifty day moving average price is $127.38 and its two-hundred day moving average price is $120.91.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.